Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
Pentagamavunon-1 (PGV-1, 1, 2.5, 5, 7.5, 10, 15, and 20 µM) increases 5-FU's cytotoxic action on WiDr cells[1]. Pentagamavunon-1 (PGV-1, 1, 2.5, 5, and 10 µM) triggers G2/M arrest and exhibits varying effects on cell cycle progression[1].
|
---|---|
ln Vivo |
In the PDX model, pentagamavunon-1 (PGV-1, po, 20 mg/kg) shows strong anti-tumor effectiveness without apparent toxicity[1].
|
Cell Assay |
Cell Viability Assay[1].
Cell Types: Human colon carcinoma WiDr. Tested Concentrations: 1, 2.5, 5, 7.5, 10, 15, and 20 µM. Incubation Duration: 6, 12, 24, and 48 hrs (hours). Experimental Results: Dramatically enhanced the cytotoxicity of 5 -FU on WiDr cells at various concentrations during 6, 12, 24, and 48 h incubation. Cell Cycle Analysis[1]. Cell Types: WiDr cells. Tested Concentrations: 1, 2.5, 5, and 10 µM. Incubation Duration: 24 h. Experimental Results: The non-treated WiDr cells demonstrated cell accumulation in G1, S, and G2/M phase about 50.85%, 36.11% and 13.04%, respectively. |
Animal Protocol |
Animal/Disease Models: Human cancer cells in a xenograf mouse model[2].
Doses: 20mg/kg. Route of Administration: PO every 2 days for 20 days. Experimental Results: demonstrated little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other effects in behavior and macroscopic appearance. Thus, PGV-1 was sufciently potent to suppress tumor formation in vivo, but demonstrated little or no obvious adverse effects on the normal lineage of cells. |
References |
[1]. Edy Meiyanto, et al. Curcumin Analog Pentagamavunon-1 (PGV-1) Sensitizes Widr Cells to 5-Fluorouracil Through Inhibition of NF-κB Activation. Asian Pac J Cancer Prev. 2018 Jan 27;19(1):49-56.
[2]. Beni Lestari, et al. Pentagamavunon-1 (PGV-1) Inhibits ROS Metabolic Enzymes and Suppresses Tumor Cell Growth by Inducing M Phase (Prometaphase) Arrest and Cell Senescence. Sci Rep . 2019 Oct 16;9(1):14867. |
Molecular Formula |
C23H24O3
|
---|---|
Molecular Weight |
348.43
|
CAS # |
27060-70-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C1/C(=C/C2C=C(C)C(=C(C)C=2)O)/CC/C/1=C\C1C=C(C)C(=C(C)C=1)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 50 mg/mL (143.50 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (5.97 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: 2.08 mg/mL (5.97 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8700 mL | 14.3501 mL | 28.7002 mL | |
5 mM | 0.5740 mL | 2.8700 mL | 5.7400 mL | |
10 mM | 0.2870 mL | 1.4350 mL | 2.8700 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.